Advertise Your Biotechnology, Pharmaceutical, Healthcare, or Medical Company To Investors

Life Science Investors Start Here

Amplify your company's brand and news by partnering with the largest platform dedicated to connecting investors with emerging life science stocks.

Life Science CEOs, IR Reps, and Digital Agencies Take Notice

Health Stocks Hub (HSH) is 100% dedicated to publicly traded biotech, pharma, medical, and health technology stocks. We reach the web's largest and most targeted niche of investors specifically focused on identifying new investment opportunities within the life sciences sector and its associated industries. Our flexible campaigns allow companies to rapidly launch broad market awareness programs as well as deploy targeted investor outreach strategies across a variety of mediums and outlets:

Daily Newsletter

Disseminate your news through our flagship daily morning newsletter and reach institutional investors, private equity firms, analysts and retail investors.

Platform Promotion

Build broad market awareness and relay your value proposition to our highly targeted audience across the feature rich HSH platform.

Investor Network

Start growing your distribution network or leverage our existing audience through enhanced analytics, remarketing campaigns, lead generation and more.

Put your news in front of investors, private equity firms, and analysts

Our flagship daily newsletter is the only of its kind and includes daily compilation and distribution. This double opt-in subscriber newsletter is distributed Monday-Friday to institutional and retail investors, brokers, analysts and more.

Health Stocks Brief for

Today's Top Headlines

Today's Top Health Stock News

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from its Phase 1 randomized, double-blind, placebo... Read More

Vertex Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

Teva Pharmaceutical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Abivax Announces a Change to the Composition of its Board of Directors

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Inotiv Completes Equity Offering for Net Proceeds of Approximately 24.0 M

OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Promote your company to investors across the entire platform

Gain full exposure across the entire Health Stocks Hub platform through featured placement, branded news and stock quotes, banner rotation, featured profiles, video capsules, and much more.